Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Myriad Genetics (MYGN) Net Margin (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Net Margin for 17 consecutive years, with 3.77% as the latest value for Q4 2025.

  • On a quarterly basis, Net Margin rose 1646.0% to 3.77% in Q4 2025 year-over-year; TTM through Dec 2025 was 44.38%, a 2917.0% decrease, with the full-year FY2025 number at 44.38%, down 2918.0% from a year prior.
  • Net Margin was 3.77% for Q4 2025 at Myriad Genetics, up from 13.32% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 14.7% in Q3 2021 to a low of 155.09% in Q2 2025.
  • A 5-year average of 22.81% and a median of 14.6% in 2023 define the central range for Net Margin.
  • Peak YoY movement for Net Margin: surged 19773bps in 2021, then crashed -13774bps in 2025.
  • Myriad Genetics' Net Margin stood at 4.73% in 2021, then tumbled by -403bps to 23.79% in 2022, then soared by 33bps to 15.87% in 2023, then dropped by -27bps to 20.23% in 2024, then surged by 81bps to 3.77% in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Net Margin are 3.77% (Q4 2025), 13.32% (Q3 2025), and 155.09% (Q2 2025).